Business Description
Novartis AG
NAICS : 325412
ISIN : ARDEUT112521
Share Class Description:
BUE:NVS: CedearDescription
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.5 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 0.66 | |||||
| Debt-to-EBITDA | 1.24 | |||||
| Interest Coverage | 11.72 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.91 | |||||
| Beneish M-Score | -3.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.1 | |||||
| 3-Year EBITDA Growth Rate | 1.6 | |||||
| 3-Year EPS without NRI Growth Rate | -0.1 | |||||
| 3-Year FCF Growth Rate | 0.6 | |||||
| 3-Year Book Growth Rate | 2.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 19 | |||||
| Future 3-5Y Total Revenue Growth Rate | -1.57 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.6 | |||||
| 9-Day RSI | 46.29 | |||||
| 14-Day RSI | 47.56 | |||||
| 6-1 Month Momentum % | 72.85 | |||||
| 12-1 Month Momentum % | 185.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | |||||
| Quick Ratio | 0.83 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 143.37 | |||||
| Days Sales Outstanding | 52.21 | |||||
| Days Payable | 98.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.88 | |||||
| Dividend Payout Ratio | 0.11 | |||||
| 3-Year Dividend Growth Rate | 3.8 | |||||
| Forward Dividend Yield % | 0.88 | |||||
| 5-Year Yield-on-Cost % | 0.99 | |||||
| 3-Year Average Share Buyback Ratio | 2.2 | |||||
| Shareholder Yield % | 8.58 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.65 | |||||
| Operating Margin % | 18 | |||||
| Net Margin % | 13.34 | |||||
| FCF Margin % | 24.48 | |||||
| ROE % | 14.69 | |||||
| ROA % | 6.75 | |||||
| ROIC % | 8.86 | |||||
| ROC (Joel Greenblatt) % | 90.01 | |||||
| ROCE % | 13.09 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.06 | |||||
| Forward PE Ratio | 13.74 | |||||
| PE Ratio without NRI | 25.88 | |||||
| Shiller PE Ratio | 17.38 | |||||
| Price-to-Owner-Earnings | 12.23 | |||||
| PEG Ratio | 4.31 | |||||
| PS Ratio | 3.36 | |||||
| PB Ratio | 5.1 | |||||
| Price-to-Free-Cash-Flow | 15.19 | |||||
| Price-to-Operating-Cash-Flow | 12.27 | |||||
| EV-to-EBIT | 18.92 | |||||
| EV-to-Forward-EBIT | 16.61 | |||||
| EV-to-EBITDA | 10.18 | |||||
| EV-to-Forward-EBITDA | 11 | |||||
| EV-to-Revenue | 3.46 | |||||
| EV-to-Forward-Revenue | 4.45 | |||||
| EV-to-FCF | 15.74 | |||||
| Price-to-Projected-FCF | 1.2 | |||||
| Price-to-Median-PS-Value | 0.94 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.63 | |||||
| Earnings Yield (Greenblatt) % | 5.29 | |||||
| FCF Yield % | 6.75 | |||||
| Forward Rate of Return (Yacktman) % | 12.99 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novartis AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 13,426,653.311 | ||
| EPS (TTM) (ARS) | 1782.427 | ||
| Beta | 0 | ||
| Volatility % | 43.21 | ||
| 14-Day RSI | 47.56 | ||
| 14-Day ATR (ARS) | 897.165916 | ||
| 20-Day SMA (ARS) | 20850.5 | ||
| 12-1 Month Momentum % | 185.78 | ||
| 52-Week Range (ARS) | 7128.98 - 24062.5 | ||
| Shares Outstanding (Mil) | 1,027.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis AG Stock Events
| Event | Date | Price(ARS) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novartis AG Frequently Asked Questions
What is Novartis AG(BUE:NVS)'s stock price today?
The current price of BUE:NVS is ARS20554.50. The 52 week high of BUE:NVS is ARS24062.50 and 52 week low is ARS7128.98.
When is next earnings date of Novartis AG(BUE:NVS)?
The next earnings date of Novartis AG(BUE:NVS) is 2024-02-01 Est..
Does Novartis AG(BUE:NVS) pay dividends? If so, how much?
The Dividend Yield %  of Novartis AG(BUE:NVS) is 0.88% (As of Today), Highest Dividend Payout Ratio of Novartis AG(BUE:NVS) was 1.04. The lowest was 0.11. And the median was 0.85. The  Forward Dividend Yield % of Novartis AG(BUE:NVS) is 0.88%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers